RU93005355A - Фармакологические композиции - Google Patents

Фармакологические композиции

Info

Publication number
RU93005355A
RU93005355A RU93005355/14A RU93005355A RU93005355A RU 93005355 A RU93005355 A RU 93005355A RU 93005355/14 A RU93005355/14 A RU 93005355/14A RU 93005355 A RU93005355 A RU 93005355A RU 93005355 A RU93005355 A RU 93005355A
Authority
RU
Russia
Prior art keywords
pharmacological compositions
lesions
excretions
psoriasis
malignant
Prior art date
Application number
RU93005355/14A
Other languages
English (en)
Other versions
RU2119333C1 (ru
Inventor
Боллаг Вернер
Франсис Гриппо Джозеф
Левин Артур
Original Assignee
Хоффманн Ля Рош АГ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хоффманн Ля Рош АГ filed Critical Хоффманн Ля Рош АГ
Publication of RU93005355A publication Critical patent/RU93005355A/ru
Application granted granted Critical
Publication of RU2119333C1 publication Critical patent/RU2119333C1/ru

Links

Claims (1)

  1. Фармакологические композиции, в том числе 9-цис ретиноевая кислота, ее соли и сложные эфиры могут использоваться при лечении злокачественных и предзлокачественных поражений эпителия, лучевых повреждений кожи, заболеваний, вызванных усиленным салоотделением, и псориаза.
RU93005355A 1992-01-22 1993-01-20 Фармацевтический состав RU2119333C1 (ru)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US82392892A 1992-01-22 1992-01-22
US82378692A 1992-01-22 1992-01-22
US82374192A 1992-01-22 1992-01-22
US823741 1992-01-22
US823928 1992-01-22
US823786 1992-01-22
US82464792A 1992-01-23 1992-01-23
US824647 1992-01-23

Publications (2)

Publication Number Publication Date
RU93005355A true RU93005355A (ru) 1995-09-27
RU2119333C1 RU2119333C1 (ru) 1998-09-27

Family

ID=27505866

Family Applications (1)

Application Number Title Priority Date Filing Date
RU93005355A RU2119333C1 (ru) 1992-01-22 1993-01-20 Фармацевтический состав

Country Status (20)

Country Link
EP (1) EP0552624B1 (ru)
JP (1) JP3631259B2 (ru)
CN (2) CN1068200C (ru)
AT (1) ATE194077T1 (ru)
AU (1) AU667864B2 (ru)
CA (1) CA2087251C (ru)
CY (1) CY2251B1 (ru)
CZ (1) CZ282548B6 (ru)
DE (1) DE69328910T2 (ru)
DK (1) DK0552624T3 (ru)
ES (1) ES2148184T3 (ru)
GR (1) GR3034323T3 (ru)
HU (2) HU212734B (ru)
IL (1) IL104450A (ru)
NO (1) NO302274B1 (ru)
NZ (1) NZ245686A (ru)
PH (1) PH31621A (ru)
PT (1) PT552624E (ru)
RU (1) RU2119333C1 (ru)
TW (1) TW226329B (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056954B2 (en) 1991-12-18 2006-06-06 The Salk Institute For Biological Studies Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
ATE163544T1 (de) 1991-12-18 1998-03-15 Salk Inst For Biological Studi Mitteln zur modulierung von verfahren durch retinoid rezeptoren und dafür nützliche verbindungen
US5968989A (en) 1991-12-18 1999-10-19 The Salk Institute For Biological Studies Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
US7655699B1 (en) 1992-04-22 2010-02-02 Eisai Inc. Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
US5962731A (en) * 1992-04-22 1999-10-05 Ligand Pharmaceuticals Incorporated Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US5549888A (en) * 1994-01-31 1996-08-27 Procter & Gamble Aqueous topical anti-acne compositions of low pH
US5534261A (en) * 1995-01-17 1996-07-09 University Of Southern California Retinoid-based compositions and method for preventing adhesion formation using the same
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
US5821254A (en) * 1995-02-17 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer
US5807900A (en) * 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
WO1996032935A1 (en) * 1995-04-21 1996-10-24 Ligand Pharmaceuticals Incorporated Inhibition of apoptosis in cells expressing fas-ligand following activation
DE19523079A1 (de) * 1995-06-26 1997-01-02 Basf Ag Ester und Amide der 9(Z)-Retinsäure
US6028052A (en) * 1995-09-18 2000-02-22 Ligand Pharmaceuticals Incorporated Treating NIDDM with RXR agonists
KR19990045756A (ko) * 1995-09-18 1999-06-25 윌리암 엘. 레스페스 Ｒｘｒ 작용제를 이용하는 ｎｉｄｄｍ 치료 방법
TW442459B (en) * 1996-04-15 2001-06-23 Hoffmann La Roche Retinoid compounds, pharmaceutical composition comprising same and process for the preparation thereof
FR2765480B1 (fr) 1997-07-07 1999-09-10 Oreal Utilisation pour le revetement des matieres keratiniques d'un materiau polymerique hybride ; compositions cosmetiques ou dermatologiques
WO1999005161A1 (en) 1997-07-25 1999-02-04 Ligand Pharmaceuticals Incorporated HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARη) GENE REGULATORY SEQUENCES AND USES THEREFOR
WO1999048529A1 (en) * 1998-03-20 1999-09-30 Warner-Lambert Company Retinoid-glitazone combinations
NZ514662A (en) 1999-04-07 2004-01-30 Sankyo Co Amine derivatives
JP5249484B2 (ja) * 2001-12-11 2013-07-31 第一三共株式会社 医薬組成物
US20050245440A1 (en) * 2002-04-05 2005-11-03 University Of Utah Research Foundation Regulation of a novel colon specific retinol dehydrogenase by apc and cdx2
AU2003270414A1 (en) * 2002-09-06 2004-03-29 Oregon Health And Science University Effect of vitamin a gel on paranasal sinus mucosal regeneration
EP1527774A1 (en) 2003-11-03 2005-05-04 Basilea Pharmaceutica AG New formulation for retinoid-containing soft gelatin capsules
JP4825957B2 (ja) * 2005-03-29 2011-11-30 国立大学法人 鹿児島大学 抗腫瘍剤
AU2009352678B2 (en) 2009-09-15 2015-05-21 Eluminex Biosciences (Suzhou) Limited Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle
WO2011129765A1 (en) * 2010-04-16 2011-10-20 Davos Life Science Pte. Ltd. Synergistic interaction of at least one vitamin e component and tyrosinase inhibitors for dermatological applications
NZ603331A (en) 2010-04-19 2015-02-27 Quadra Logic Tech Inc Therapeutic regimens and methods for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency
MX370928B (es) 2012-03-01 2020-01-08 Retinagenix LLC El uso de 9-cis-retinil acetato para mejorar la función visual de un sujeto que padece de pérdida de la función visual originada por una deficiencia retinoide endógena de 11-cis retinal.
JP6182728B2 (ja) * 2012-11-02 2017-08-23 国立大学法人名古屋大学 幹細胞を標的とした薬効及び毒性の評価法
WO2022051831A1 (pt) 2020-09-11 2022-03-17 Chemyunion Ltda. Composição, uso de composição, método cosmético e método para modular a produção de sebo
WO2023168608A1 (en) * 2022-03-08 2023-09-14 Mastery Biotech Co., Ltd. Pharmaceutical composition including retinoic acid and carbohydrate and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA713539B (en) * 1970-06-23 1972-02-23 Hoffmann La Roche Pharmaceutical compositions
AU610587B2 (en) * 1987-04-06 1991-05-23 Daltex Medical Sciences, Inc. Treatment of aged skin with oral 13-cis-retinoic acid
US4994491A (en) * 1988-12-14 1991-02-19 Molecular Design International Dermal uses of trans-retinoids for the treatment of cancer
LU86969A1 (fr) * 1987-08-12 1989-03-08 Oreal Association de derives de pyrimidine et de retinoides en composants separes pour induire et stimuler la croissance des cheveux et diminuer leur chute
ATE163544T1 (de) * 1991-12-18 1998-03-15 Salk Inst For Biological Studi Mitteln zur modulierung von verfahren durch retinoid rezeptoren und dafür nützliche verbindungen

Similar Documents

Publication Publication Date Title
RU93005355A (ru) Фармакологические композиции
CA2087251A1 (en) Pharmaceutical compositions
RU93047799A (ru) Композиции, содержащие ретиноевые кислоты и токоферол
RU92016445A (ru) Применение амидов изоксазол-4-карбоновой кислоты и амидов гидроксиалкилиденциануксусной кислоты
ATE161419T1 (de) Kosmetische zusammensetzung, die einen lipidstoff und eine hydroxy - oder ketofettsäure enthält
CA2140545A1 (en) Use of first runnings coconut fatty acid as insect-repellent
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
KR930016100A (ko) 약제학적 조성물
ES8102141A1 (es) Un procedimiento para preparar compuestos de acido 3-cefem-4-carboxilico disustituido en las posiciones 3 y 7
DE68919009D1 (de) Verwendung von 5-Amino-salicylsäure für die Behandlung von Hautkrankheiten.
SE8102161L (sv) "3,7,11,15-tetrametyl-2,4,6,10,14-hexadekapentaensyra
RU94011321A (ru) Способ профилактики и лечения заболеваний кожи
ATE120090T1 (de) Behandlung gealterter haut mit oraler 13-cis- retinsäure.
ES2064958T3 (es) Gel acuoso a base de acido retinoico y de hidroxipropil-beta-ciclodextrina.
Cormie Perifolliculitis capitis abscedens et suffodiens
IT1211103B (it) Sostanza medicamentosa ad impiego topico per il trattamento delle affezioni provocate dalla seborrea sul cuoio capelluto umano.
IT7950765A0 (it) Composizioni farmaceutiche per il trattamento di affezioni cutanee in particolare psoriasi
DE59001796D1 (de) Verwendung einer hydroxyoctadecadiensaeure, deren zur ketoform oxidierte saeure sowie deren derivate zur therapie oestrogenabhaengiger krankheiten, sowie pharmazeutische zusammensetzungen, die diese enthalten.
RU95100066A (ru) Способ наружного лечения микозов стоп и гладкой кожи
IT1099795B (it) Composizione terapeutica per il trattamento di infezioni e malattie di animali da allevamento
IT8024347A0 (it) L'applicazione di 4-arilchinazolin-2(1h)-oni per il trattamento delle malattie autoimmuni dei tessuti connettivi.
RU94021279A (ru) Препарат для лечения и профилактики мастита крупного рогатого скота
RU92011168A (ru) Препарат для лечения гинекологических заболеваний
IT1249648B (it) Derivato salicilico antiinfiammatorio e antiaterosclerotico ad azione protratta
RU96108909A (ru) Ибупрофен и флурбипрофен как противозудное средство